Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Medro vs Nucore Health

Medro
Graded #255

Higher grade

vs+5
Nucore Health
Graded #367

Lower grade

The verdict

Medro takes it — 63.6/100 to 58.6/100.

Medro grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Medro (Medro Health Technologies, Inc.) is a telehealth brand whose GLP-1 program offers compounded semaglutide and tirzepatide, plus brand-name GLP-1s when eligible, via a partner medical group and…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMedro +14
50
36
Dose & formulationMedro +13
77
64
Clinical oversightNucore Health +11
71
82
Labs & monitoringNucore Health +1
52
53
FulfillmentMedro +25
92
67
Contract termsNucore Health +22
33
55
Medro · left barNucore Health · right bar

The numbers

MetricMedroNucore Health
WeighScore63.6/10058.6/100
GradeCC
Scorecard rank#255#367
Semaglutide$199/mo (compounded)$299/mo (starting dose, compounded)
Tirzepatide$299/mo (compounded)$199/mo (microdose tier, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
Medro

Graded #255 · C

Strengths

  • Covers both compounded semaglutide and tirzepatide and can prescribe brand-name GLP-1s when clinically appropriate.
  • LegitScript-certified (seal #50716646), available in all 50 states, with tiered pricing shown before checkout.
  • No membership fee and free expedited shipping on all orders; online intake with no appointment required in many cases.
  • Prices drop with longer commitments (semaglutide to $149/mo, tirzepatide to $224/mo on a 12-month plan).

Where it loses points

  • Does not name its compounding pharmacy or its clinical partner medical group, so the fulfillment chain is not verifiable.
  • Pricing is described as illustrative and may change by dose, pharmacy availability, and eligibility — final cost shows only at checkout.
  • Very new brand (2026, trademark pending) spanning many verticals, with a short track record in GLP-1 care.
  • Compounded medications are not FDA-approved or therapeutically equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound.
Nucore Health

Graded #367 · C

Strengths

  • Physician-owned and LegitScript Certified — strong trust signals
  • Available nationwide in all 50 states
  • Care and pharmacy fulfillment run on OpenLoop Health's licensed network
  • Broad menu — compounded GLP-1, microdose tirzepatide, NAD+, sermorelin, MIC B12

Where it loses points

  • Published pricing is gated behind the intake quiz — no upfront cost shown
  • Legal terms and privacy are posted as downloadable documents, not web pages
  • Compounded GLP-1 is not FDA-approved and prescribed off-label (per their own notice)
  • Longevity and microdose positioning is marketing; evidence varies by use

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard